Articles tagged with Prostate Tumors
The study published in Science Translational Medicine documents pre-clinical data and rationale for developing G-202 as a potential cancer therapy. G-202, combined with prodrug delivery, is effective at killing fast- and slow-growing cancers by targeting PSMA enzyme.
A new technique has been reported in the American Journal of Pathology that uses genetic abnormalities to predict prostate cancer relapse. The study found that copy number variations (CNVs) in both cancerous and non-cancerous tissues can accurately forecast recurrence, allowing for more targeted treatment approaches.
Researchers discovered a population of low-PSA prostate cancer stem cells that are resistant to hormone therapy and chemotherapy. These cells can differentiate into other cancer cell types and have long-term tumor-propagating capacity.
A compound isolated from honeybee hive propolis has been found to slow the growth of prostate cancer cells and tumors in mice by shutting down their system for detecting sources of nutrition. The compound CAPE arrests early-stage prostate cancer by suppressing proteins involved in cell proliferation, offering a promising co-treatment a...
Researchers at Thomas Jefferson University have discovered a powerful new strategy for personalized anti-cancer therapy by linking biomarker MCT4 to tumor metabolism. High levels of MCT4 are correlated with poorer overall survival and increased risk of recurrence in patients with triple negative breast cancer.
Researchers have discovered a new target for cancer therapy, TDO enzyme, which enables tumors to evade immune rejection. A novel inhibitor of TDO has shown promising results in preclinical studies.
Researchers at Trinity College Dublin have developed a new vaccine to treat cancer by manipulating the immune response. The vaccine, which has shown high effectiveness in pre-clinical trials, overcomes obstacles that have hindered previous cancer vaccines.
Marissa Rylander, a Virginia Tech associate professor, has received the Y.C. Fung Young Investigator Award for her novel research combining nanotechnology, laser therapy, and dynamic imaging to study tumor progression and develop cancer treatments. Her patented 'holey scaffold' device allows for minimally invasive sensing of biological...
A study published in the Journal of Experimental Medicine reveals that protein BMP7 signals prostate tumor cells to enter a state of dormancy. Withdrawal of this protein restarts tumor growth, offering potential new therapies to prevent recurrence.
Researchers have identified a genetic vulnerability in an aggressive type of prostate cancer, found in fewer than 2% of tumors but potentially treatable with targeted therapy. The study discovered that a specific drug, PHA-739358, showed dramatic responses in animal models and is now being tested in human trials.
A combination of REGN910 and aflibercept has been shown to inhibit tumor growth more effectively than single-agent therapies, with significant improvements in antitumor effects observed in animal models. The treatment also induced increased tumor hypoxia, leading to rapid cell death and dramatic regression in colorectal tumors.
The UCSF MRI technology center has been awarded a $5.5 million NIH grant to advance new magnetic resonance imaging (MRI) technology that can detect cancer's aggressiveness more accurately. The technique, tested in a small pilot study, uses a new instrument to boost the MRI signal and measure enzyme activity in real time.
Researchers at Fox Chase Cancer Center have developed a new technique for delivering radiation therapy using a multileaf collimator, significantly reducing treatment time and minimizing radiation exposure to surrounding tissues. The new method achieves better target coverage and dose sharpness than traditional CyberKnife technology.
A team of Seattle researchers has mapped the genome of advanced prostate cancers, identifying 'hypermutation' as a key driver of disease progression and potential resistance to therapies. The study provides clues for early detection and new therapeutic strategies.
Researchers report the presence of alternative lengthening of telomeres (ALT) in various cancers, including bladder, cervix, and lung tumors. ALT allows cancer cells to grow indefinitely, making it a potential target for anti-cancer therapies.
A team of medical engineers at TUM has developed a sensor chip that measures oxygen levels in tumors and transmits data wirelessly to doctors. This technology aims to make cancer therapies more targeted and less aggressive for patients.
Researchers found that PHLPP1 and PTEN tumor suppressor genes work together to prevent lethal prostate cancer. The study suggests that monitoring gene transcription activity could predict patient outcomes and identify best candidates for clinical trials.
Researchers have identified a new hormonal pathway driving advanced prostate cancer, which can be targeted by drugs. This discovery will help develop accurate biomarkers and improve treatment outcomes for resistant tumors.
A new imaging technology reveals that metabolic shifts in cancer cells occur even before detectable tumors form, suggesting an early diagnostic tool for liver cancer. The study also shows that tumor metabolism changes precede tumor regression, offering potential strategies for cancer treatment and more effective therapies.
Mayo Clinic researchers have developed a human vaccine that uses viruses to stimulate the immune system to attack and cure prostate cancer in mice. The vaccine has shown promise in treating other aggressive cancers, such as lung, brain, and pancreatic cancer, with no apparent side effects.
Researchers have developed a new cancer vaccine using a library of DNA that targets multiple tumor proteins, avoiding overreaction by the immune system. Early studies in mice show successful treatment results without severe side effects.
A new targeted therapy, G-1, has been shown to halt the growth of tumors in animals with advanced prostate cancer resistant to hormone therapy. The treatment works by targeting and activating protein GPR30, which sensitizes tumor cells to its inhibiting effects.
Researchers from NCI found XMRV unlikely to cause prostate cancer or chronic fatigue syndrome in humans. The virus arose due to genetic recombination of two mouse viruses, not present in original human tumor samples.
Researchers at Queensland University of Technology found a mushroom compound, polysaccharopeptide (PSP), to be 100% effective in suppressing prostate tumor development in mice. PSP targets prostate cancer stem cells and prevents tumour formation without causing side effects.
Researchers find increased MAN2C1 levels enhance prostate cancer recurrence and metastasis, highlighting a potential target for blocking tumor progression. The study could lead to the development of new treatments for patients with advanced prostate cancer.
A Swedish research team found that surgery significantly reduces prostate cancer mortality risk, even among men with low-risk tumours. The study followed 347 patients and found that surgical patients had a lower risk of dying from prostate cancer than those who underwent watchful waiting.
Researchers at MD Anderson Cancer Center discovered WWP2's role in regulating PTEN, a tumor suppressor protein. WWP2 binding to PTEN leads to its degradation, allowing cancer cells to grow uncontrollably.
A large-scale study of 769 men with low-grade prostate cancer found that closely monitoring the disease without immediate treatment does not raise the risk of death. Men who undergo active surveillance are less likely to need subsequent surgery or radiation if their cancer progression is carefully monitored.
Researchers at Queen's University Belfast have developed a new drug that prevents tumor growth by cutting off their blood supply, showing promise for treating prostate and breast cancers. The treatment targets tumor angiogenesis using an entirely different pathway than existing therapies.
Researchers have found a new method for detecting prostate cancer that analyzes non-tumor tissue, potentially improving diagnosis accuracy. This approach could help reduce the number of repeat biopsies and improve patient outcomes.
The study reveals several new prostate cancer genes, including those disrupting tumor suppressor proteins and rearrangements that create new genes. These findings may provide insights into the disease's development and suggest potential diagnostic markers and new treatments for aggressive forms of prostate cancer.
A Phase III trial found that everolimus significantly improved progression-free survival for patients with advanced pancreatic neuroendocrine tumors, reducing the risk by 65% and increasing median progression-free survival by over six months. Common side effects include stomatitis, rash, diarrhea, fatigue, and infections.
Whole genome sequencing reveals new genes tied to prostate cancer growth, including those disrupting tumor suppressors and heat shock proteins. The study identifies genomic rearrangements that may be driving cancer development and suggests a link between gene activity and DNA rearrangement.
Researchers at UT MD Anderson Cancer Center found that a specific microRNA, miR-34a, suppresses prostate cancer stem cells and metastasis by targeting the surface protein CD44. The study provides a strong rationale for developing new treatment options for prostate cancer.
Researchers have developed nanoparticles that deliver the cancer drug cisplatin more effectively and safely, reducing its potentially severe side effects. The new particles successfully shrink tumors in mice using only one-third of the conventional dose.
Researchers found that a slight rise in PSA levels among men taking dutasteride was a stronger indicator of prostate cancer than rising PSA levels in men on a placebo. The study suggests that the drug enhances the ability to detect high-grade cancers, making the PSA test more effective for early diagnosis and treatment.
Researchers developed an imaging technology that uses ultrasound to accurately identify tumors and assess their aggressiveness. This can lead to better treatment and cost savings in healthcare.
A new technology uses metabolic imaging to rapidly assess prostate tumor presence and aggressiveness in real-time. The initial results validate preclinical research linking tumor metabolism speed to growth aggressiveness.
Mount Sinai researchers discovered a hormone receptor linked to several malignant tumor types, suggesting a new diagnostic or therapeutic target. The receptor's presence may be used to improve cancer detection and develop imaging agents that can visualize early tumors.
Researchers found that TAL1 promotes the expression of NKX3.1 in T cell acute lymphoblastic leukemia cells, driving their growth and proliferation. Eliminating NKX3.1 halted the growth of these cancerous cells in culture and after injection into mice.
Researchers at Stanford University have developed a new technique that triples the speed of MRI imaging, allowing for real-time tracking of moving lung tumors. This could lead to more effective radiation therapy and improved patient outcomes.
UT Southwestern researchers found blocking a specific enzyme step can halt tumor growth. The study suggests this approach may provide new therapy options for patients with end-stage prostate cancer, which has limited treatment choices.
A team of investigators has identified a series of proteins that may make it easier to diagnose the more metastatic forms of prostate cancer. The study uncovers a protein named Siah2, which initiates a cascade of molecular events that turns a non-malignant tumor into a metastatic neuroendocrine tumor.
A six-year study by researchers at Henry Ford Hospital found that heavier prostate cancer patients have larger tumors. The study of 3,327 patients revealed a direct correlation between BMI and tumor volume, suggesting that obesity may contribute to the aggressive nature of the disease.
Professor Richard Radke is leading a new study to develop novel computer automation techniques to reduce prep time of intensity-modulated radiation therapy (IMRT) from several hours to minutes. IMRT delivers non-uniform doses of radiation to tumors, but requires manual adjustments and optimizations.
Researchers have developed a powerful new technique for analyzing genome data from single tumor cells. The breakthrough allows scientists to study the biology of tumor development and identify dangerous cells in small samples. By profiling individual cells, researchers can understand genetic changes that occur as cancer progresses.
Researchers discovered a peptide called iRGD that co-administers drugs to tumors, increasing treatment efficacy and reducing side effects. The peptide has been shown to enhance the therapeutic effect of anti-cancer drugs without creating new chemical entities.
A new microchip-based device enhances rapid and comprehensive analysis of circulating tumor cells, revealing key biological properties. The improved system allows for better monitoring of prostate cancer treatment responses.
A four-year international trial found that dutasteride reduced the chances of being diagnosed with mid-range aggressiveness tumors, which account for most prostate cancers. The drug was effective at reducing the risk of medium-grade tumors by 31.4% in men with a family history of prostate cancer.
Rylander aims to create a multi-component treatment planning computational model for nanoparticle-medicated laser therapy to achieve selective and effective cancer treatment. She will also develop a course on nanotherapeutics and establish an education and outreach plan for underprivileged schools.
Researchers successfully froze breast cancer in patients who refused surgery, with no localized treatment recurrences seen for up to five years and no significant complications noted. The study used image-guided, multiprobe cryotherapy, which provided safe and effective breast conservation with minimal discomfort.
Researchers have found that tumors can be treated with extreme heat or moderate heat using ultrasound techniques, showing promise for a new cancer therapy option. Hyperthermia has been shown to increase radiation damage and enhance chemotherapy treatments.
Researchers developed biological probes that can stick to and light up tumors in mice, allowing for more accurate tumor removal and improved survival rates. The probes enabled surgeons to visualize areas of tumors they wouldn't ordinarily see, reducing cancer cells by 90% on average.
Researchers used MR spectroscopy to analyze the biochemical makeup of prostate glands and accurately identified the location of tissue confirmed to be malignant. The approach achieved an accuracy of over 90% in detecting stage II tumors and could potentially guide treatment planning.
Researchers Yoed Rabin and Kenji Shimada are developing an interactive simulator for cryosurgical procedures, combined with a computerized tutor to evaluate quality. This project aims to enhance surgical training by practicing virtual cryosurgical procedures, motivating surgeons to learn and improve their skills.
Researchers have identified a peptide called iRGD that specifically targets and penetrates cancerous tumors, delivering diagnostic particles and medicines. This breakthrough could improve cancer treatment and reduce side effects.
Research led by Ohio State University found that aggressive prostate cancers have small, irregular blood vessels, while slow-growing tumors have more normal-appearing vessels. This study suggests using tumor blood vessel architecture to guide therapy and potentially improve long-term survival for patients.
A new Tel Aviv University drug carrier delivers existing life-saving therapies directly to cancer tumors, reversing growth and inhibiting tumor growth by 50%. The innovative formulation targets tumors without affecting normal healthy cells, offering a potential solution for various forms of cancers and diseases.
A study found improved survival rates for men with localized prostate cancer diagnosed between 1992 and 2002 compared to earlier eras. The 10-year prostate cancer-specific mortality rate was 8.3% for well-differentiated tumors, lower than previous reports.
A new study found that men diagnosed with low-risk prostate cancers who deferred treatment were still doing fine an average of eight years after their diagnosis. Only half of these men eventually underwent any treatment 10 to 15 years post-diagnosis, preserving their quality of life.